Novo Nordisk

IRS: 911144498
Novo Nordisk

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

1931 (91 years)
Investor RelationsSEC
21 billion (2021)

Want to see more? Sign up!